Literature DB >> 2493328

Identification of osteoblast-specific monoclonal antibodies.

T Nakano1, S Kimoto, K Tanikawa, K T Kim, M Higaki, T Kawase, S Saito.   

Abstract

A series of four antibodies against rat osteoblasts have been produced using the hybridoma technique. After bone cells isolated from newborn rat calvariae by a sequential digestion procedure were cultured for 3 days, the cells were trypsinized and further maintained in rotation cultures overnight. Out of the cultured bone cells alkaline phosphatase-positive cells were sorted by flow cytometry and used as immunogens. The clones secreting the antibodies were selected on the basis of the abilities of these antibodies to bind to the bone cells but not to fibroblasts from neonatal rat head skins, in an enzyme-linked immunosorbent assay. Clones of two hybridomas, designated AOB-1 and AOB-2, were used to characterize the antigenic determinant(s) in osteogenic cells. The antibody showed the reactivity with isolated alkaline phosphatase-positive cells, osteogenic tissue cells in newborn rat calvaria, and mandibula, but not with the cells in head skin, lung, kidney, liver, or stomach as determined by immunofluorescence study. Western blot analysis has identified the antigenic determinants possessing apparent molecular weights of 210,000, 110,000, 65,000, 58,000, 40,000, 36,000, 32,000, 28,000, 25,000, 17,000, and 15,000 of osteoblast-rich monolayer cultured cells. According to the cell surface detection with biotin-avidin protein blotting technique, these fractions appear to be present as components of the cell surface of the osteoblast.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493328     DOI: 10.1007/bf02556568

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  23 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Identification of osteocytes in osteoblast-like cell cultures using a monoclonal antibody specifically directed against osteocytes.

Authors:  P J Nijweide; R J Mulder
Journal:  Histochemistry       Date:  1986

3.  Demonstration of a high affinity Ca2+ ATPase in rat liver plasma membranes.

Authors:  Y Iwasa; Y Iwasa; K Higashi; K Matsui; E Miyamoto
Journal:  Biochem Biophys Res Commun       Date:  1982-03-30       Impact factor: 3.575

4.  A high affinity calcium-stimulated magnesium-dependent ATPase in rat liver plasma membranes. Dependence of an endogenous protein activator distinct from calmodulin.

Authors:  S Lotersztajn; J Hanoune; F Pecker
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

5.  Stimulation of creatine kinase BB activity by parathyroid hormone and by prostaglandin E2 in cultured bone cells.

Authors:  D Sömjen; A M Kaye; I Binderman
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

6.  Purification and characterization of the Ca2+-ATPase of plasma membranes from Ehrlich ascites mammary carcinoma cells.

Authors:  R Wetzker; F D Böhmer; R Klinger; E Müller; H Hegewald; M Scheven; R Grosse
Journal:  Biochim Biophys Acta       Date:  1986-01-16

7.  Cell surface characterization of the human osteoclast: phenotypic relationship to other bone marrow-derived cell types.

Authors:  M A Horton; E F Rimmer; D Lewis; J A Pringle; K Fuller; T J Chambers
Journal:  J Pathol       Date:  1984-12       Impact factor: 7.996

8.  Antibodies against osteosarcoma and colon cancer.

Authors:  M J Embleton; A Brown; B Gunn; V S Byers; R W Baldwin
Journal:  Behring Inst Mitt       Date:  1984-05

9.  Identification of osteoclast-specific monoclonal antibodies.

Authors:  M J Oursler; L V Bell; B Clevinger; P Osdoby
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

10.  Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line.

Authors:  M J Embleton; B Gunn; V S Byers; R W Baldwin
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.